About Cancer Genetics
Cancer Genetics is a company based in Rutherford (United States) founded in 1999.. Cancer Genetics has raised $9.81 million across 8 funding rounds from investors including HHS. The company has 110 employees as of December 31, 2019. Cancer Genetics has completed 7 acquisitions, including BioServe Biotechnologies, Bioserve and GenomeWeb. Cancer Genetics operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter Rutherford, United States
- Employees 110 as on 31 Dec, 2019
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$9.81 M (USD)
in 8 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jan 18, 2021
- Investors
-
Employee Count
110
as on Dec 31, 2019
-
Investments & Acquisitions
BioServe Biotechnologies
& 6 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cancer Genetics
Cancer Genetics has successfully raised a total of $9.81M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(01 Jan 2006)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Post-IPO - Cancer Genetics | Valuation |
investors |
|
| Jul, 2018 | Amount | Post-IPO - Cancer Genetics | Valuation |
investors |
|
| Dec, 2017 | Amount | Post-IPO - Cancer Genetics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cancer Genetics
Cancer Genetics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cancer Genetics
Cancer Genetics has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include BioServe Biotechnologies, Bioserve and GenomeWeb. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developing a commercial scale printer for the high-volume growth and differentiation of stem cells and stem cell products.
|
2014 | ||||
|
Provider of integrated preclinical services
|
2003 | ||||
|
DNA synthesis, sequencing, extraction, and biomarker discovery services are provided.
|
2002 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Cancer Genetics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cancer Genetics Comparisons
Competitors of Cancer Genetics
Cancer Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cancer Genetics
Frequently Asked Questions about Cancer Genetics
When was Cancer Genetics founded?
Cancer Genetics was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Where is Cancer Genetics located?
Cancer Genetics is headquartered in Rutherford, United States. It is registered at Rutherford, New Jersey, United States.
Who is the current CEO of Cancer Genetics?
John A Roberts is the current CEO of Cancer Genetics.
Is Cancer Genetics a funded company?
Cancer Genetics is a funded company, having raised a total of $9.81M across 8 funding rounds to date. The company's 1st funding round was a Post-IPO of $7M, raised on Jan 01, 2006.
How many employees does Cancer Genetics have?
As of Dec 31, 2019, the latest employee count at Cancer Genetics is 110.
What does Cancer Genetics do?
Cancer Genetics was founded in 1999 and is headquartered in Rutherford, United States. Operations are centered in the biotechnology sector, with a focus on genomic diagnostics for oncology. Proprietary tests and a reference laboratory are provided to generate patient-specific genetic data. This information is utilized by physicians for cancer diagnosis, treatment monitoring, and personalization of therapies. Services encompass both product development and laboratory support across the United States.
Who are the top competitors of Cancer Genetics?
Cancer Genetics's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.
How many acquisitions has Cancer Genetics made?
Cancer Genetics has made 7 acquisitions, including BioServe Biotechnologies, Bioserve, and GenomeWeb.
Who are Cancer Genetics's investors?
Cancer Genetics has 1 investor. Key investors include HHS.